Literature DB >> 26045990

Correlated expression levels of endothelin receptor B and Plexin C1 in melanoma.

Mayuko Y Kumasaka1, Ichiro Yajima1, Machiko Iida1, Hiro Takahashi2, Yuji Inoue3, Satoshi Fukushima3, Hironobu Ihn3, Kozue Takeda4, Yuji Naito5, Toshikazu Yoshikawa5, Masashi Kato1.   

Abstract

Discussion concerning the effect of endothelin receptor B (Ednrb) on melanoma continues because Ednrb has been reported to have both tumor promoting and suppressive effects for melanoma. In order to examine Ednrb-related signaling in melanomagenesis, DNA microarray analysis for a melanoma from a RFP/RET-transgenic mouse (RET-mouse) and a melanoma from an Ednrb-heterozygously deleted RET-mouse [Ednrb(+/-);RET-mouse], in both of which melanoma spontaneously develops, was performed in this study. We found that the expression level of Plexin C1 (PlxnC1), a suppressor for melanoma, in a melanoma from an Ednrb(+/-);RET-mouse was drastically decreased compared to that in a melanoma from a RET-mouse. Therefore, we further examined the correlation between Ednrb and PlxnC1 expression levels in melanomas. PlxnC1 transcript expression levels in melanomas from Ednrb(+/-);RET-mice were lower than those in melanomas from RET-mice. A strong correlation between Ednrb and PlxnC1 transcript expression levels (R = 0.78, p < 0.01) was also found in melanomas from both RET-mice and Ednrb(+/-);RET-mice. Correspondingly, there was a significant correlation between transcript (R = 0.80; p < 0.01) and protein (R = 0.60; p < 0.01) expression levels of EDNRB and PLXNC1 in human primary melanomas. Together with our results showing that the expression level of PLXNC1 transcript was reduced in EDNRB-depleted human melanoma cells, our results showing positively correlated expression levels of Ednrb/EDNRB and PlxnC1/PLXNC1 in melanoma suggest that PlxnC1/PLXNC1 is involved in the Ednrb/EDNRB-mediated suppressive effect on melanoma.

Entities:  

Keywords:  Ednrb; Plexin C1; melanoma

Year:  2015        PMID: 26045990      PMCID: PMC4449439     

Source DB:  PubMed          Journal:  Am J Cancer Res        ISSN: 2156-6976            Impact factor:   6.166


  12 in total

1.  The temporal requirement for endothelin receptor-B signalling during neural crest development.

Authors:  M K Shin; J M Levorse; R S Ingram; S M Tilghman
Journal:  Nature       Date:  1999-12-02       Impact factor: 49.962

2.  Semaphorin 7a promotes spreading and dendricity in human melanocytes through beta1-integrins.

Authors:  Glynis A Scott; Lindy A McClelland; Alex F Fricke
Journal:  J Invest Dermatol       Date:  2007-08-02       Impact factor: 8.551

3.  CD109 expression levels in malignant melanoma.

Authors:  Yuichiro Ohshima; Ichiro Yajima; Mayuko Y Kumasaka; Takeshi Yanagishita; Daisuke Watanabe; Masahide Takahashi; Yuji Inoue; Hironobu Ihn; Yoshinari Matsumoto; Masashi Kato
Journal:  J Dermatol Sci       Date:  2010-01-07       Impact factor: 4.563

4.  Association between endothelin receptor B nonsynonymous variants and melanoma risk.

Authors:  Nadem Soufir; Roubila Meziani; Jean-Jacques Lacapère; Guylene Bertrand; Frederic Fumeron; Agnes Bourillon; Bénédicte Gérard; Vincent Descamps; Béatrice Crickx; Laurence Ollivaud; Alain Archimbaud; Céleste Lebbe; Nicole Basset-Seguin; Philippe Saiag; Bernard Grandchamp
Journal:  J Natl Cancer Inst       Date:  2005-09-07       Impact factor: 13.506

5.  A phase II study of bosentan, a dual endothelin receptor antagonist, as monotherapy in patients with stage IV metastatic melanoma.

Authors:  Richard Kefford; Jane McNeil Beith; Guy Arthur Van Hazel; Michael Millward; James Marshall Trotter; David Keith Wyld; Rada Kusic; Revati Shreeniwas; Adele Morganti; Andrea Ballmer; Eleonor Segal; Oliver Nayler; Martine Clozel
Journal:  Invest New Drugs       Date:  2006-10-05       Impact factor: 3.850

6.  L-cysteine as a regulator for arsenic-mediated cancer-promoting and anti-cancer effects.

Authors:  Masashi Kato; Mayuko Y Kumasaka; Kozue Takeda; Khaled Hossain; Machiko Iida; Ichiro Yajima; Yuji Goto; Nobutaka Ohgami
Journal:  Toxicol In Vitro       Date:  2010-12-30       Impact factor: 3.500

7.  Endothelin receptor B inhibition triggers apoptosis and enhances angiogenesis in melanomas.

Authors:  Ronit Lahav; Mario-Luca Suvà; Donata Rimoldi; Paul H Patterson; Ivan Stamenkovic
Journal:  Cancer Res       Date:  2004-12-15       Impact factor: 12.701

8.  Plexin C1, a receptor for semaphorin 7a, inactivates cofilin and is a potential tumor suppressor for melanoma progression.

Authors:  Glynis A Scott; Lindy A McClelland; Alex F Fricke; Anne Fender
Journal:  J Invest Dermatol       Date:  2008-11-06       Impact factor: 8.551

9.  A randomized, double-blind, placebo-controlled study of high-dose bosentan in patients with stage IV metastatic melanoma receiving first-line dacarbazine chemotherapy.

Authors:  Richard F Kefford; Philip R Clingan; Benjamin Brady; Andrea Ballmer; Adele Morganti; Peter Hersey
Journal:  Mol Cancer       Date:  2010-03-30       Impact factor: 27.401

10.  A novel mouse model for de novo Melanoma.

Authors:  Mayuko Y Kumasaka; Ichiro Yajima; Khaled Hossain; Machiko Iida; Toyonori Tsuzuki; Tamio Ohno; Masahide Takahashi; Masashi Yanagisawa; Masashi Kato
Journal:  Cancer Res       Date:  2010-01-01       Impact factor: 12.701

View more
  3 in total

1.  Construction of possible integrated predictive index based on EGFR and ANXA3 polymorphisms for chemotherapy response in fluoropyrimidine-treated Japanese gastric cancer patients using a bioinformatic method.

Authors:  Hiro Takahashi; Nahoko Kaniwa; Yoshiro Saito; Kimie Sai; Tetsuya Hamaguchi; Kuniaki Shirao; Yasuhiro Shimada; Yasuhiro Matsumura; Atsushi Ohtsu; Takayuki Yoshino; Toshihiko Doi; Anna Takahashi; Yoko Odaka; Misuzu Okuyama; Jun-Ichi Sawada; Hiromi Sakamoto; Teruhiko Yoshida
Journal:  BMC Cancer       Date:  2015-10-16       Impact factor: 4.430

Review 2.  SEMAPHORINS and their receptors: focus on the crosstalk between melanoma and hypoxia.

Authors:  Elisabetta Valentini; Marta Di Martile; Donatella Del Bufalo; Simona D'Aguanno
Journal:  J Exp Clin Cancer Res       Date:  2021-04-15

3.  Transcription factor LSF (TFCP2) inhibits melanoma growth.

Authors:  Yuji Goto; Ichiro Yajima; Mayuko Kumasaka; Nobutaka Ohgami; Asami Tanaka; Toyonori Tsuzuki; Yuji Inoue; Satoshi Fukushima; Hironobu Ihn; Mikiko Kyoya; Hiroyuki Ohashi; Tamihiro Kawakami; Dorothy C Bennett; Masashi Kato
Journal:  Oncotarget       Date:  2016-01-19
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.